advertisement
Click Here

PPD deal worth $44 m for Ranbaxy.

Economic Times (New Delhi, India), March, 2007

Mar. 10--BANGALORE, India -- The recent in-licensing deal between Indian pharma major Ranbaxy and PPD, a Nasdaq-listed contract research organisation (CRO), could be worth up to $44 million for the Gurgaon-based company, the Wilmington, North Carolina-based CRO has said.

In its form 8-K filings with Securities and Exchange Commission (SEC), PPD has also admitted to paying Ranbaxy $250,000 as a one-time licence fee.

PPD (2006 sales $1.24 billion) is one of the world's leading CROs along with Quintiles and Covance. CROs specialise in global clinical trials to test the efficacy and commercial viability of molecules.

In-licensing refers to the arrangement by which one contracting party buys the right to use a patent from another. Such deals are...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here